21.8 C
New York
Wednesday, June 10, 2026

Tag: TC BioPharm

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...

Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight

The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on...

Global Gamma Delta T Cell Cancer Therapy Market Shaped by Over 25 Clinical Trials

The report indicates >25 clinical trials, with the highest phase being Phase II/III as of June 2025. The US and China lead with >20 trials. Gamma Delta T Cell therapy, promising in treating blood cancers like AML, faces challenges in solid tumors. TC Biopharm's OmnImmune and TCB008 show potential, highlighting advances in this novel immunotherapy domain.
The report indicates >25 clinical trials, with the highest phase being Phase II/III as of June 2025. The US and China lead with >20 trials. Gamma Delta T Cell therapy, promising in treating blood cancers like AML, faces challenges in solid tumors. TC Biopharm's OmnImmune and TCB008 show potential, highlighting advances in this novel immunotherapy domain.

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

First patient in Cohort B achieved CR after 2nd dose of TCB008EDINBURGH, Scotland, June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTC BioPharm